頂流基金經理大手筆"捧場",公募搶籌定增最高浮盈超530%
格隆匯10月28日丨據券商中國,截至10月27日,今年以來公募基金參與的項目中,超七成項目能夠取得浮盈,平均收益率達28.35%。其中,大成新銳產業與大成睿景兩隻基金參與雲天化定增事項的收益率超五倍,傅鵬博的睿遠成長價值參與上機數控定增浮盈約2.5億元,所有基金單次參與定增平均浮盈約爲635.48萬元。有機構認爲,在今年風格多變的震盪行情中,定增投資策略整體的折扣率表現較去年更加突出,年內的定增投資整體的收益表現值得期待。但因爲明星基金經理參與定增是在其建立的投資組合中配置相應的個股,而散戶投資者的投資邏輯和投資週期或與大型公募基金差異較大,因此普通投資者不能簡單“抄作業”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.